Jury Convicts Martin Shkreli of Fraud

06:35 EDT 9 Aug 2017 | CHEManager

Martin Shkreli, the eccentric former CEO of Turing Pharmaceuticals, who made headlines in 2015 by jacking up the price of Daraprim (pyrimethamine), a 62-year-old drug used to treat toxoplasmosis, from $13.50 to $750 per pill, was convicted of fraud on Aug. 4. After a four-week trial, the jury in Brooklyn, New York, found the 34-year-old guilty on three out of eight counts of fraud, two of which could carry a maximum sentence of 20 years in prison.

Original Article: Jury Convicts Martin Shkreli of Fraud


More From BioPortfolio on "Jury Convicts Martin Shkreli of Fraud"

Quick Search

Relevant Topic

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...